Case Study: Unlocking access to MSK-ACCESS® for robust liquid biopsy analysis
Memorial Sloan Kettering Cancer Center (MSK) is a world leading institution for cancer treatment and research. We’re collaborating with MSK to expand access to precision cancer analysis capabilities worldwide.
Genomic Diagnostics, Australia
Genomic Diagnostics improve equity of access to hereditary cancer genomic analysis in Australia with the SOPHiA DDM™ Hereditary Cancer Solution v1.1.
TomaLab Advanced Biomedical Assays
A Clinical Case Study about the value of the SOPHiA DDM™ HRD Dx Solution in clinical routine
The Andalusian Health Service use the CE IVD-marked SOPHiA DDM™️ Dx Hereditary Cancer Solution to detect an Alu insertion (Clinical Decision Support Only) in an ovarian cancer case
The SOPHiA DDM™️ Platform enables the quick and confident assessment of ~1000 hereditary cancer samples per year.
The Andalusian Health Service address a colorectal cancer case with the CE IVD-marked SOPHiA DDM™️ Dx Hereditary Cancer Solution
The CNV detection algorithm in SOPHiA DDM™️ efficiently identified a complex duplication in MSH2.
Ontario Group of Hospitals use a future-proof custom SOPHiA DDM™ Comprehensive Hereditary Cancer Solution to be in line with Ontario guidelines.
Hospitals maximize efficiency of their laboratory workflow, fulfil updated Ontario guidelines and keep testing in-house.
